Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis.
Sign Up to like & getrecommendations! Published in 2022 at "Respiratory medicine"
DOI: 10.2139/ssrn.4184350
Abstract: INTRODUCTION Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease for which two effective antifibrotics, nintedanib and pirfenidone, are available. However, many patients receive a reduced dosage or pause treatment due to side effects… read more here.
Keywords: idiopathic pulmonary; nintedanib pirfenidone; antifibrotic treatment; reduction ... See more keywords
Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Thoracic Medicine"
DOI: 10.4103/atm.atm_206_22
Abstract: BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive age-related lung disease causing relentless fibrosis of the lung parenchyma. Currently, pirfenidone and nintedanib are the two antifibrotic drugs, approved for the treatment of IPF. Both… read more here.
Keywords: real life; idiopathic pulmonary; nintedanib pirfenidone; pulmonary fibrosis ... See more keywords